Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC
Status:
Not yet recruiting
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
A phase 2 randomised controlled trial will be performed in which the efficacy and safety of
standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external
beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT;
consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98
patients with LAVC, registered from eight national medical centres.